Thyroid Cancer Pipeline Offers Promising New Options for Treatment | DelveInsight
02 mai 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, May 02, 2022 (GLOBE NEWSWIRE) -- Thyroid Cancer Pipeline Offers Promising New Options for Treatment | DelveInsight Thyroid Cancer Pipeline involves 40+ key companies continuously...
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
05 nov. 2021 05h58 HE
|
Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Global Cancer Biopsy Market Analysis Report 2021: Advent of Liquid Biopsy & Transition of Novel Oncology Diagnostics from Bench to Clinics - Forecast to 2027
20 sept. 2021 04h43 HE
|
Research and Markets
Dublin, Sept. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Cancer Biopsy Market Size, Share & Trends Analysis Report 2021-2027" report has been added to ResearchAndMarkets.com's offering. The global...
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
11 févr. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement...
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
17 déc. 2019 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
18 juil. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics...
International Thyroid Cancer Survivors' Conference Brings Together Survivors, Caregivers, and Expert Speakers in Chicago, October 19-21
02 oct. 2018 10h01 HE
|
ThyCa
CHICAGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ThyCa: Thyroid Cancer Survivors' Association, Inc., has secured an impressive lineup of more than 35 expert speakers for the 21st International Thyroid...
Interpace Diagnostics Announces CIGNA’s Expansion of Coverage to Now Include ThyraMIR®
26 juil. 2018 08h37 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides...
Interpace Diagnostics Group Reports First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
15 mai 2018 08h00 HE
|
Interpace Diagnostics Group, Inc.
Revenue Grew 39% Over the Prior Year’s Quarter and 10% Over the Prior Period Record Quarterly Revenue of $4.8 Million and Record Quarterly Cash Receipts of $4.4 Million Cash & Cash Equivalents...
Interpace Diagnostics Announces Launch of New Thyroid Test
14 mai 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
BOSTON, May 14, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides...